Project Grant R01AR087478
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $467K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Syracuse, NY 13244, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $547,767 to the University of Rochester on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate host mechanisms governing Staphylococcus aureus persistence during implant-associated osteomyelitis. The research uses humanized mouse models and multi-omic analysis of human T cells to understand why some patients resolve acute bone infections while others...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Northeastern University $652,195 on June 17, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and test surface-modified, cartilage-targeting exosomes as non-viral gene delivery vehicles for osteoarthritis treatment. The project engineers charge-reversed cationic exosomes derived from mesenchymal stem cells, anchored with arginine-rich peptide motifs, to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Cornell University $184,648 on January 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fund a doctoral research project investigating the mast cell–IL-33 axis in post-traumatic osteoarthritis. The project, led by PhD student Abigail Loucks under sponsor Aimee Colbath and co-sponsor Tristan Maerz, evaluates the temporal role of mast cells in post-traumatic...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Ohio University $665,615 on August 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of a novel SIRT5 allele in osteoarthritis development. The research examines how altered SIRT5 activity in chondrocytes disrupts cellular metabolism and joint inflammation to increase osteoarthritis susceptibility. The recipient will conduct studies on a rare...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Duke University $1,054,899 on September 19, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to conduct research on JAK-specific signaling in post-traumatic osteoarthritis-associated joint degeneration and pain. Duke University's Office of Research Administration will identify which Janus kinases (JAK1, JAK2, and/or TYK2) mediate both cartilage catabolism and nociceptive...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), an operating division of the Department of Health and Human Services National Institutes of Health, awarded Cornell University $390,956 on May 28, 2026, to develop a novel platform for osteocyte-specific therapeutic modulation using peptide-functionalized nanoparticles to target Wnt signaling in bone remodeling. The work addresses the therapeutic challenge of reaching osteocytes embedded within mineralized bone...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Research Foundation for the State University of New York $576,328 on August 18, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research to define the role of macrophage-derived thrombospondin-1 (TSP1) in strain-induced fracture fibrosis and to test whether TSP1 inhibition can restore regenerative healing in fracture nonunion. The research...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Carnegie Mellon University $486,545 on July 3, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and validate in vivo cartilage mechanics as a sensitive biomarker for early knee osteoarthritis detection. The research establishes a novel metric based on cartilage deformation and composition changes in response to common physical...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Rush University Medical Center $643,185 on June 10, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds development of validated, patient-specific computational models to predict polyethylene wear in total shoulder arthroplasty (TSA) and identify modifiable surgical, design, and rehabilitation targets to improve implant...